AdvaMed Says New Study Will Support Revamping Of Japan Reimbursement
This article was originally published in The Gray Sheet
A detailed study comparing the cost of bringing medical devices to market in Japan to that of doing so in the U.S. is due out soon from AdvaMed
You may also be interested in...
Japan's regulatory and reimbursement systems came under fire this week from lawmakers on Capitol Hill and attendees of AdvaMed's international conference in Arlington, Va
AdvaMed President Steve Ubl aims to have FDA meeting a 180-day review deadline for expedited PMAs in the next three to five years and to revamp Japan's reimbursement system in the next two years
Faster reviews of low-risk medical devices in Japan are on the horizon as the fledgling Pharmaceutical & Medical Devices Agency prepares to implement new review processes, effective April 1